U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

Showing 1451 - 1460 of 1802 results

Status:
Possibly Marketed Outside US
Source:
NCT00797589: Phase 4 Interventional Completed Valve Surgery
(2009)
Source URL:

Class (Stereo):
CHEMICAL (RACEMIC)


Malic acid is a tart-tasting organic dicarboxylic acid that contributes to the taste of many sour or tart foods such as apples. Sodium Malate is the sodium salt of Malic Acid. Malic Acid and Sodium Malate can be found in a wide range of cosmetics and personal care products. Sodium Malate functions as a skin conditioning agent-humectant. As a food additive, Sodium Malate has the E number E350. Sodium Malate has demonstrated protective effect on cisplatin-induced toxicity in mice. Sodium malate could become a useful agent for the reduction of CDDP-induced toxicity, particularly nephrotoxicity and hepatotoxicity.
Status:
Possibly Marketed Outside US
Source:
NCT02847091: Phase 4 Interventional Completed Type 2 Diabetes Mellitus
(2016)
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)



Ipragliflozin L-proline is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. It was developed and marketed as Suglat® by Astellas cooperating with Kotobuki Pharmaceutical and Merck Sharp & Dohme, and approved by Pharmaceuticals and Medical Devices Agency of Japan (PMDA) on Jan 17, 2014. It is indicated for the treatment of type 2 diabetes.
Status:
Possibly Marketed Outside US
Source:
Japan:Ethyl L-Cysteine Hydrochloride
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)


Conditions:

Ethyl cysteinate is derivative of semi-essential proteinogenic amino acid Cysteine. Ethyl cysteinate is widely used in food additive, cosmetic, pharmaceutical area. Ethyl cysteinate is membrane-permeable, readily enters peripheral tissues and the brain, and increases intracellular pools of cysteine in these tissues via a membrane-associated carboxylesterase. The increased availability of cysteine directly alters the redox status of cells and enhances glutathione production. The enhanced biovailability of L-cysteine and L-glutathione would also promote the direct formation of the S-nitrosothiols, L-S-nitrosocysteine and L-S-nitrosoglutathione and the overall S-nitrosylation status of functional proteins in cells.
Zinc lactate is used to eliminate halitosis. Halitosis (commonly known as bad breath) is a condition affecting many people and one of the most usual reasons why people go look for a dentist’s advice. The main origin of halitosis is related to the volatile sulphur compounds (VSC) produced by the different bacterial colonies found on the tongue and in the gingival crevices. Zinc lactate is a very effective solution to neutralize the VSC and an excellent ingredient for mouthwashes and toothpastes.
Status:
Possibly Marketed Outside US
Source:
NCT01998620: Phase 4 Interventional Unknown status Hepatitis B
(2013)
Source URL:

Class (Stereo):
CHEMICAL (EPIMERIC)



S-Adenosylmethionine (often referred to as SAMe) is a methyl donor and a cofactor for enzyme-catalyzed methylations, including catechol O-methyltransferase (COMT) and DNA methyltransferases (DNMT). Although present in all cells, it is concentrated in liver where 85% of all methylation reactions occur. SAM is anti-apoptotic in normal hepatocytes and normal colon epithelial cells but pro-apoptotic in liver human hepatocellular carcinoma (HCC), HepG2 cells and colon cancer cells. Because of structural instability, stable salt forms of SAM are required for its use as an oral drug. The commonly used salts: tosylate, butanedisulfonate, disulfate tosylate, disulfate ditosylate, and disulfate monotosylate. SAMe has been marketed in some European countries since the mid-1980s for the treatment of depression and for other medical conditions such as osteoarthritis (joint disease that causes joint pain and stiffness), fibromyalgia (widespread pain and stiffness). In addition, it is used to treat liver disease and migraine headaches. However, it is not formally approved in the UK for the treatment of depression, and in the USA, it is classified only as a dietary supplement. Some research suggests that it is more effective than placebo in treating mild-to-moderate depression and is just as effective as antidepressant medications without the side effects (headaches, sleeplessness, and sexual dysfunction). In addition, antidepressants tend to take 6 to 8 weeks to begin working, while It seems to begin more quickly. Researchers are not sure how SAMe works to relieve depression. But they speculate it might increase the amount of serotonin in the brain just as some antidepressants do. Many studies have examined injectable forms of SAMe, not oral supplements.
Status:
Possibly Marketed Outside US

Class (Stereo):
CHEMICAL (EPIMERIC)

Zilascorb (2H) is a deuterated derivative of benzylidene ascorbate. Its mechanism of action is reversible protein synthesis inhibition, and it was observed experimentally that deuterated compound is more effective than a non-deuterated form of a drug. Zilascorb(2H) has shown antitumor activity against human malignant melanoma grown as xenografts in nude mice. The effect was manifest only after prolonged daily treatment and was quickly reversible when treatment was stopped. Anticancer activity of zilascorb(2H) was assessed in clinical trials. The drug demonstrated efficacy both when administered as an intravenous infusion, and when administered in oral form. Development of zilascorb was discontinued in the late 1990s.
mixture
Status:
Investigational
Source:
NCT01546571: Phase 3 Interventional Terminated Melanoma
(2012)
Source URL:

Class:
MIXTURE

Showing 1451 - 1460 of 1802 results